This study showed this combination regimen of anti-PD-L1 plus anti-VEGF had significantly longer overall and progression-free survival compared to the sorafenib, which was the first successful regimen as a first-line treatment for the unresectable HCC beyond sorafenib. This evidence concerns the gene CD274 and hepatocellular carcinoma.